A multi-institution phase i trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML) Academic Article uri icon

Overview

MeSH Major

  • Epigenesis, Genetic
  • Gene Expression Regulation, Leukemic
  • Genetic Heterogeneity
  • Leukemia, Myeloid, Acute

abstract

  • The recommended phase II dose of ruxolitinib is 20 mg twice daily. We demonstrate that ruxolitinib has promising activity in CMML with particular benefit in those with disease-related B symptoms that warrants further study. Clin Cancer Res; 22(15); 3746-54. ©2016 AACRSee related commentary by Solary, p. 3707.

publication date

  • August 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5278764

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-15-2781

PubMed ID

  • 26858309

Additional Document Info

start page

  • 3746

end page

  • 54

volume

  • 22

number

  • 15